Group 1 - Wang Philip Li increased his stake in Baixinan-B (02185) by 10,000 shares at an average price of 6.66 HKD per share, totaling 66,600 HKD [1] - After the increase, the total number of shares held by Wang Philip Li is 85,017,700, representing a holding percentage of 36.07% [1]

Group 1 - The core point of the news is that Wang Philip Li has increased his stake in Baixinan-B (02185) by purchasing 10,000 shares at a price of HKD 6.66 per share, totaling HKD 66,600. After this transaction, his total shareholding amounts to 84,997,700 shares, representing a 36.06% ownership stake [1][2]

Summary of Key Points Core Viewpoint - Wang Philip Li increased his stake in Baixinan-B (02185) by purchasing 10,000 shares at a price of HKD 6.66 per share, totaling HKD 66,600, which reflects confidence in the company's future prospects [1] Company Actions - The purchase occurred on November 27, indicating active investment behavior by Wang Philip Li [1] - After the transaction, Wang Philip Li's total shareholding in Baixinan-B reached 84,997,700 shares, representing a 36.06% ownership stake [1]

Group 1 - The stock of Baixinan-B (02185.HK) rose nearly 12% in the afternoon trading session, reaching an increase of 11.93% at the time of reporting [1] - The current trading price is 6.85 HKD per share [1] - The trading volume amounted to 4.3019 million HKD [1]

Core Viewpoint - 百心安-B's stock price increased by nearly 12% following the announcement of the registration of its Iberis RDN system in New Zealand, highlighting positive market sentiment towards the company's advancements in medical technology [1] Company Developments - 百心安-B's subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully registered the Iberis RDN system with New Zealand's Medsafe [1] - The Iberis RDN system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods, enhancing safety, efficacy, and cost-effectiveness of RDN procedures [1] - The ultimate goal of the company is to provide outpatient RDN surgeries for patients worldwide [1] Market Performance - As of the report, 百心安-B's stock was trading at 6.85 HKD with a trading volume of 430.19 million HKD, reflecting strong investor interest [1]

Core Viewpoint - The stock of Baixinan-B (02185) surged nearly 12% following the announcement of the registration of its Iberis RDN system in New Zealand, marking a significant milestone for the company in the renal denervation market [1] Group 1: Company Developments - Baixinan-B's subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully registered the Iberis RDN system with New Zealand's Medsafe [1] - The Iberis RDN system is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - The TRA method enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1] Group 2: Market Position and Goals - The company's ultimate goal is to provide outpatient renal denervation surgeries to patients worldwide [1] - The Iberis RDN system received CE marking in Europe in 2016, indicating its established presence in the international market [1]

Core Viewpoint - The announcement highlights the registration of the Iberis RDN system in New Zealand, marking a significant milestone for the company in the renal denervation market [1] Company Summary - The Iberis RDN system, developed by the company's subsidiary Shanghai Antong Medical Technology Co., Ltd., has received approval from New Zealand's Medicines and Medical Devices Safety Authority (Medsafe) [1] - The Iberis RDN system is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - The TRA method enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1] - The company's ultimate goal is to provide outpatient renal denervation surgeries for patients worldwide [1] - The Iberis RDN system received CE marking in Europe in 2016, indicating its compliance with European health, safety, and environmental protection standards [1]

Core Viewpoint - The announcement highlights that the Iberis® RDN system developed by the company's subsidiary has received registration from New Zealand's Medsafe, marking a significant milestone in the company's product offerings [1] Company Summary - The Iberis® RDN system is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - TRA enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1] - The ultimate goal of the company is to provide outpatient renal denervation surgeries to patients worldwide [1] - The company obtained the CE mark for the Iberis® RDN system in Europe in 2016 [1]

Core Viewpoint - The announcement highlights that the Iberis RDN system developed by Shanghai Antong Medical Technology Co., Ltd. has received registration from New Zealand's Medsafe, marking a significant milestone for the company in the renal denervation market [1]. Group 1: Product Development - The Iberis RDN system is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1]. - TRA enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1]. Group 2: Market Goals - The ultimate goal of the company is to provide outpatient renal denervation surgeries for patients worldwide [1]. - The Iberis RDN system received CE marking in Europe in 2016, indicating its compliance with European health and safety standards [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不會就本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 Shanghai Bio-heart Biological Technology Co., Ltd. 上海百心安生物技術股份有限公司 本 公 告 乃 由 上 海 百 心 安 生 物 技 術 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 情 況 的 最 新 資 料。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，最 近，本 公 司 附 屬 公 司 上 海 安 通 醫 療 科 技 有 限 公 司（「安 通」）研 發 的Iberis®多 極 腎 動 脈 射 頻 消 融 導 管 系 統（「Iberis® RDN系 統」）已 在 新 西 蘭 完 成 新 西 蘭 藥 品 和 醫 療 器 械 ...